Improved tau PET SUVR quantification in 4-repeat tau phenotypes with 
[18F]PI-2620

Bischof, Gérard N.; Brendel, Matthias; Barthel, Henryk; Theis, Hendrik; Barbe, Michael; Bartenstein, Peter; Claasen, Joseph; Danek, Adrian; Höglinger, Günter; Levin, Johannes; Marek, Ken; Neumaier, Bernd; Palleis, Carla; Patt, Marianne; Rullmann, Michael; Saur, Dorothee; Schroeter, Matthias L.; Seibyl, John; Song, Mengmeng; Stephens, Andrew; Sabri, Osama; Drzezga, Alexander; van Eimeren, Thilo

doi:10.2967/jnumed.123.265930

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Improved tau PET SUVR quantification in 4-repeat tau phenotypes with [18F]PI-2620

MPS-Authors

Rullmann, Michael
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;

/persons/resource/persons19981

Schroeter, Matthias L.
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Clinic for Cognitive Neurology, University of Leipzig, Germany;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

Bischof_2024.pdf
(出版社版), 806KB

付随資料 (公開)

There is no public supplementary material available

引用

Bischof, G. N., Brendel, M., Barthel, H., Theis, H., Barbe, M., Bartenstein, P., Claasen, J., Danek, A., Höglinger, G., Levin, J., Marek, K., Neumaier, B., Palleis, C., Patt, M., Rullmann, M., Saur, D., Schroeter, M. L., Seibyl, J., Song, M., Stephens, A., Sabri, O., Drzezga, A., & van Eimeren, T. (2024). Improved tau PET SUVR quantification in 4-repeat tau phenotypes with [18F]PI-2620. Journal of Nuclear Medicine, 65(6), 952-955. doi:10.2967/jnumed.123.265930.

引用: https://hdl.handle.net/21.11116/0000-000F-2C35-5

要旨

We used a new data-driven methodology to identify a set of reference regions that enhanced the quantification of the SUV ratio of the second-generation tau tracer 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine ([18F]PI-2620) in a group of patients clinically diagnosed with 4-repeat tauopathy, specifically progressive supranuclear palsy or cortical basal syndrome. The study found that SUV ratios calculated using the identified reference regions (i.e., fusiform gyrus and crus-cerebellum) were significantly associated with symptom severity and disease duration. This establishes, for the first time to our knowledge, the suitability of [18F]PI-2620 for tracking disease progression in this 4-repeat disease population. This is an important step toward increased clinical utility, such as patient stratification and monitoring in disease-modifying treatment trials. Additionally, the applied methodology successfully optimized reference regions for automated detection of brain imaging tracers. This approach may also hold value for other brain imaging tracers.